Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Slides:

Advertisements

Similar presentations

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Advertisements

Treatment with ipilimumab

Treatment with ipilimumab

Dose-escalation patient response.

Figure 2 Response after initial increase in total tumour burden

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Targeting T Cell Co-receptors for Cancer Therapy

Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates.

Clinical responses in patients.

PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,

Volume 13, Issue 2, Pages (October 2015)

Supplementary Table S1. H-scores of ICAM-1, VCAM-1 and IP-10 expression in tumors of melanoma patients before and after ipilimumab or Ipi-Bev treatment.

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Quantification of MHC-I, β2m, and T-cell subsets.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Correlation of RSPO expression to LGR5 expansion in gastric cancer.

A, PTEN loss signature score in resected SQCLC brain metastases.

PD-L1 expression by melanocytes is observed in geographic association with TILs but does not depend on BRAF V600E. PD-L1 expression by melanocytes is observed.

CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. CD94/NKG2A expression and presence is higher on tumor-infiltrating immune.

Supplementary Figure S1

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

AXL is not expressed in human prostate tumors.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

PTEN expression regulates autophagy in tumor cells, reducing T cell–mediated killing. PTEN expression regulates autophagy in tumor cells, reducing T cell–mediated.

Plasma and tissue EGFR allele analyses.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

PD-L1 is expressed in breast cancer.

PD-1 expression in ovarian cancer.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Activation status of CD8+ T cells.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Immune profiling of patient-derived organotypic tumor spheroids.

Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.

Defining the eTME genes.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

Supplementary Table 2. Antibodies and conditions used for the IHC studies.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Fig. 3. Association between peak CTL019 expansion and response.

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. A, overview of IHC for PTEN in advanced metastatic melanoma patients. PTEN expression was evaluated by a Clinical Laboratory Improvement Amendments (CLIA)–certified PTEN IHC assay. Representative PTEN staining pictures for each category are shown. B, a waterfall plot of the best objective response in each anti–PD-1-treated patient. Thirty-nine cases of melanoma patients treated with anti–PD-1 antibody were stratified based on the expression of PTEN. Tumor burden was measured by the sum of longest diameters of target lesions. The best objective response of anti–PD-1 antibody was evaluated by the maximum change of tumor burden based on baseline. C, comparison of tumor reduction after PD-1 therapy in patients with or without PTEN loss. The P value of the comparison was determined by the Wilcoxon rank-sum test. D, increased percentage of PTEN absent in melanoma patients with failed initial expansion of TILs (≤40 × 106 TIL after initial expansion). A 2 × 2 contingency table was made based on the frequency distribution of PTEN expression status and the success of initial TIL growth in the ACT cohort. The P value (P = 0.04) was determined by the Fisher exact t test. E, correlation of CD8+ T-cell infiltration with PTEN expression status of stage IIIB/C melanoma patient tumors. F, examples of CD8 staining in two patients with clonal PTEN expression. Weiyi Peng et al. Cancer Discov 2016;6:202-216 ©2016 by American Association for Cancer Research